» Articles » PMID: 6712202

Pharmacokinetics of Cefpiramide (SM-1652) in Humans

Overview
Specialty Pharmacology
Date 1984 Feb 1
PMID 6712202
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics of cefpiramide (SM-1652) were studied after the intravenous administration of single or multiple doses to 21 healthy volunteers. The cefpiramide concentration in plasma at time zero after a bolus intravenous injection of 500 or 1,000 mg was 152 or 303 micrograms/ml, respectively. The maximum cefpiramide level in plasma at the end of a 1-h infusion of 1,000 or 2,000 mg was 166 or 317 micrograms/ml, respectively. The mean plasma half-life of cefpiramide in 15 subjects who received a single dose of 500 or 1,000 mg was 4.44 h. There was no evidence of drug accumulation in plasma when 500 or 1,000 mg of cefpiramide was administered 11 times at 12-h intervals. Urinary excretion of cefpiramide over a 24-h period was ca. 22.5%, regardless of the intravenous administration technique and the dosage. Fecal recoveries of cefpiramide varied from 0 to 36.9% in different subjects.

Citing Articles

Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.

Day C, Bailly B, Guillon P, Dirr L, Jen F, Spillings B mBio. 2021; 12(2).

PMID: 33785634 PMC: 8092326. DOI: 10.1128/mBio.03681-20.


Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase.

White M, Lin W, Cheng X J Phys Chem Lett. 2020; 11(21):9144-9151.

PMID: 33052685 PMC: 7571306. DOI: 10.1021/acs.jpclett.0c02421.


Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase.

White M, Lin W, Cheng X bioRxiv. 2020; .

PMID: 32817950 PMC: 7430582. DOI: 10.1101/2020.08.09.243246.


Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

Huh Y, Smith D, Feng M Xenobiotica. 2011; 41(11):972-87.

PMID: 21892879 PMC: 4181675. DOI: 10.3109/00498254.2011.598582.


Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics.

Feng M, Lou X, Brown R, Hutchaleelaha A Pharm Res. 2000; 17(4):410-8.

PMID: 10870984 DOI: 10.1023/a:1007520818956.


References
1.
RIEGELMAN S, Loo J, Rowland M . Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci. 1968; 57(1):117-23. DOI: 10.1002/jps.2600570123. View

2.
RIEGELMAN S, Loo J, Rowland M . Concept of a volume of distribution and possible errors in evaluation of this parameter. J Pharm Sci. 1968; 57(1):128-33. DOI: 10.1002/jps.2600570125. View

3.
Lee F, Pfeffer M, Van Harken D, Smyth R, Hottendorf G . Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob Agents Chemother. 1980; 17(2):188-92. PMC: 283756. DOI: 10.1128/AAC.17.2.188. View

4.
Seddon M, Wise R, Gillett A, Livingston R . Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980; 18(2):240-2. PMC: 283977. DOI: 10.1128/AAC.18.2.240. View

5.
Bolton W, Scheld W, Spyker D, Sande M . Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency. Antimicrob Agents Chemother. 1981; 19(5):821-5. PMC: 181529. DOI: 10.1128/AAC.19.5.821. View